Healthcare
Live Price
Offline$8.93
+5.18% today
1Y Change
+47.36%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Prothena Corporation plc (PRTA) is a Healthcare stock with a market cap of $570.00M and listed on NASDAQ. The stock last traded around $8.93 and up 47.4% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -92.8%, EPS growth of -99.6%, a dividend yield of 0.0%. What stands out right now is revenue -92.8%, EPS -99.6%, free cash flow -8.9% with operating margin -2247.5% and ROIC -75.4%. Valuation already assumes a fairly strong business story at price/sales 59.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PRTA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRTA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PRTA Max Drawdown
-31.28%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PRTA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$200.6M
+272.1% YoY
FY Net Income
$67.0M
+157.3% YoY
Free Cash Flow
$92.0M
+184.2% YoY
Revenue Growth
-92.8%
EPS Growth
-99.6%
Gross Margin
-208.6%
Net Margin
-2520.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 10M | 135M | 91M | 54M | 201M |
| Gross Profit | 6M | 135M | 91M | 54M | 201M |
| Operating Income | -185M | -155M | -191M | -132M | 72M |
| EBITDA | -197M | -154M | -190M | -131M | 73M |
| Net Income | -244M | -122M | -147M | -117M | 67M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 308M | 471M | 619M | 710M | 579M |
| Total Assets | 327M | 547M | 696M | 758M | 609M |
| Total Liabilities | 46M | 60M | 135M | 136M | 143M |
| Shareholder Equity | 280M | 487M | 561M | 622M | 466M |
| Total Debt | 14M | 11M | 12M | 6M | 12M |
| Net Debt | -294M | -461M | -607M | -704M | -567M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
93M
+185.1% YoY
Capital Expenditures
575K
-23.9% YoY
Free Cash Flow
92M
+184.2% YoY
Key ratios
Gross Margin
-208.6%
Operating Margin
-2247.5%
Net Margin
-2520.6%
ROE
-73.0%
Debt / Equity
0.05x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.